Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prime Medicine, Inc.

2.01
+0.01000.50%
Post-market: 1.96-0.0500-2.49%19:39 EDT
Volume:2.06M
Turnover:4.28M
Market Cap:256.60M
PE:-1.22
High:2.30
Open:2.06
Low:1.94
Close:2.00
Loading ...

Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Nuvalent (NUVL)

TIPRANKS
·
13 Nov 2024

Prime Medicine, Inc. (PRME) Receives a Buy from TD Cowen

TIPRANKS
·
13 Nov 2024

Prime Medicine Q3 EPS $(0.44) Misses $(0.39) Estimate, Sales $209.00K

Benzinga
·
13 Nov 2024

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

THOMSON REUTERS
·
13 Nov 2024

Prime Medicine, Inc. Q3 EPS USD -0.44

THOMSON REUTERS
·
13 Nov 2024

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire
·
13 Nov 2024

Prime Medicine treatment of retinal dystrophy granted orphan designation

TIPRANKS
·
26 Oct 2024

Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Oct 2024

Prime Medicine presents data from multiple studies showcasing LNP platform

TIPRANKS
·
24 Oct 2024

Prime Medicine- on Track to Initiate Ind-Enabling Activities for Wilson's Disease Program in 4Q 2024, With Ind and/or Cta Filing Expected in 1H 2026

THOMSON REUTERS
·
24 Oct 2024

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

GlobeNewswire
·
15 Oct 2024

Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
02 Oct 2024

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

Zacks
·
02 Oct 2024

Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley

TIPRANKS
·
30 Sep 2024

Prime Medicine, Inc. (PRME) Gets a Hold from Stifel Nicolaus

TIPRANKS
·
30 Sep 2024

Prime Medicine Shares up 29.8% on License Agreement With Bristol Myers Squibb for T-Cell Therapies

THOMSON REUTERS
·
30 Sep 2024